Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Boehringer Ingelheim
Boehringer Ingelheim
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
CP Wire
Wed, 10/10/18 - 10:13 am
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
Wed, 10/10/18 - 10:08 am
Jardiance
Boehringer Ingelheim
Eli Lilly
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Fierce Pharma
Fri, 10/5/18 - 08:51 pm
Boehringer Ingelheim
Eli Lilly
Tradjenta
diabetes
Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal
Endpoints
Thu, 09/13/18 - 11:30 am
Boehringer Ingelheim
ViraTherapeutics
M&A
Cooperation agreement between Boehringer Ingelheim and Tsinghua University (Beijing)
GoinPharma
Tue, 09/11/18 - 11:32 pm
Boehringer Ingelheim
Tsinghua University
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
CP Wire
Tue, 09/4/18 - 10:09 am
antibiotics
Boehringer Ingelheim
drug development
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Tue, 09/4/18 - 10:08 am
Boehringer Ingelheim
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Pharmaceutical Business Review
Sun, 08/26/18 - 12:00 pm
Boehringer Ingelheim
Eli Lilly
clinical trials
diabetes
Tradjenta
Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Fierce Biotech
Mon, 08/6/18 - 09:58 am
Boehringer Ingelheim
cystic fibrosis
Oxford BioMedica
gene therapy
Trajenta Meets Primary Endpoint in Cardiovascular Trial
CP Wire
Thu, 07/19/18 - 09:47 am
Boehringer Ingelheim
Eli Lilly
Trajenta
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Thu, 07/19/18 - 09:47 am
Boehringer Ingelheim
Eli Lilly
Trajenta
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
CP Wire
Tue, 07/17/18 - 09:56 am
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
Tue, 07/17/18 - 09:52 am
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
According to new market survey, pharma industry continues to invest heavily on basic research
GoinPharma
Thu, 07/12/18 - 09:22 am
R&D
Boehringer Ingelheim
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
CP Wire
Tue, 07/10/18 - 11:13 am
Boehringer Ingelheim
animal health
Europe
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
Tue, 07/10/18 - 09:42 am
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence adds fill-finish line to China plant
Fierce Pharma
Fri, 07/6/18 - 10:33 pm
Boehringer Ingelheim
China
drug manufacturing
biologics
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
Mon, 07/2/18 - 10:02 am
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Mon, 07/2/18 - 09:26 am
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
Mon, 06/25/18 - 09:06 pm
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
…
next ›
last »